Pharmaceutical Policies in OECD Countries
暂无分享,去创建一个
[1] A. Avery,et al. Prescribing cost savings by GP fundholders: long-term or short-term? , 1997, Health economics.
[2] David S. Salkever,et al. Pricing, Patent Loss and the Market for Pharmaceuticals , 1991 .
[3] Robert H. Ballance,et al. The World's Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy , 1992 .
[4] J. Gual. The Coherence of EC Policies on Trade, Competition and Industry , 1995 .
[5] G. Urban,et al. Information, marketing, and pricing in the U.S. antiulcer drug market. , 1995, The American economic review.
[6] Zvi Griliches,et al. Generics and New Goods in Pharmaceutical Price Indexes , 1993 .
[7] V. Paris,et al. Âge, temps et normes : une analyse de la prescription pharmaceutique , 1997 .
[8] J. M. Ferrándiz,et al. The impact of generic goods in the pharmaceutical industry. , 1999, Health economics.
[9] G. Kelly. Improving the PPI sample for prescription pharmaceuticals. , 1997, Monthly labor review.
[10] E. Kolassa. Physicians ' Perceptions of Prescription Drug Prices:: Their Accuracy and Effect on the Prescribing Decision , 1995 .
[11] F. Andersson,et al. Effective patent life of drugs in Sweden—a comparison with international studies , 1993 .
[12] T. Walley,et al. Generic prescribing: time to regulate the market? , 2000, BMJ : British Medical Journal.
[13] Henry G. Grabowski,et al. Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act , 1992, The Journal of Law and Economics.
[14] J. Hellerstein,et al. The importance of the physician in the generic versus trade-name prescription decision. , 1998, The Rand journal of economics.
[15] A. Mitchell. Update and evaluation of Australian guidelines. Government perspective. , 1996, Medical care.
[16] R. Manning. Products Liability and Prescription Drug Prices in Canada and the United States1 , 1997, The Journal of Law and Economics.
[17] W. S. Comanor,et al. The political economy of the pharmaceutical industry. , 1986, Journal of economic literature.
[18] R. Rozek. A Critique of the GAO Report on Differences in Prices for Prescription Drugs Between Canada and the United States , 1995 .
[19] Frederic M. Scherer,et al. Pricing, Profits, and Technological Progress in the Pharmaceutical Industry , 1993 .
[20] C. L. Pen. Réglementation des prix et formes de la concurrence dans l'industrie pharmaceutique , 1988 .
[21] R. Guell,et al. Estimating allocative inefficiency in the prescription drug industry , 1997 .
[22] D. Cocks,et al. Pricing Behavior of the Ethical Pharmaceutical Industry , 1974 .
[23] B. Stuart,et al. Insurance Choice and the Demand for Prescription Drugs , 1995 .
[24] H. Grabowski,et al. Longer Patents for Lower Imitation Barriers: The 1984 Drug Act , 1986 .
[25] Estimating the moral-hazard effect of supplemental medical insurance in the demand for prescription drugs by the elderly. , 1995, The American economic review.
[26] S B Soumerai,et al. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. , 1987, The New England journal of medicine.
[27] B. Gunnarsson,et al. Cost and utilisation of pharmaceuticals in Sweden. , 1997, Health policy.
[28] B. O'brien,et al. The effect of patient charges on the utilisation of prescription medicines. , 1989, Journal of health economics.
[29] J. V. Reenen,et al. Regulating Drug Prices: Where Do We Go from Here? , 1998 .
[30] F. Tapon. Life After Bills C-22 and C-91. The Furure of Canadian Generic Pharmaceutical Firms , 1992 .
[31] J. Newhouse. Free for All?: Lessons from the RAND Health Insurance Experiment , 1993 .
[32] D. Dranove. The costs of compliance with the 1962 FDA amendments. , 1991, Journal of health economics.
[33] Jean-Marie Robine,et al. The Health of Older Persons in OECD Countries: Is it Improving Fast Enough to Compensate for Population Ageing? , 1999 .
[34] Franklin M. Fisher,et al. Aggregate Price Indices, New Goods, and Generics , 1995 .
[35] W. Reekie. Price and Quality Competition in the United States Drug Industry , 1978 .
[36] N. E. Coulson,et al. Persistence in the use of pharmaceuticals by the elderly. Evidence from annual claims. , 1992, Journal of health economics.
[37] D. Schofield. RE-EXAMINING THE DISTRIBUTION OF HEALTH BENEFITS IN AUSTRALIA , 1998 .
[38] V. Suslow. Are there better ways to spell relief? : a hedonic pricing analysis of ulcer drugs , 1992 .
[39] P. Gorecki. Controlling drug expenditure in Canada: The Ontario experience , 1993 .
[40] F. Tapon,et al. Compulsory Licensing as a Policy Instrument , 1984 .
[41] P. Temin. Regulation and the choice of prescription drugs. , 1980, The American economic review.
[42] David O. Meltzer,et al. Do Important Drugs Reach the Market Sooner , 1994 .
[43] L. Ried,et al. The Effect of Drug Co-Payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance Organization , 1990, Medical care.
[44] R. Guell. Haggling for a patent: what a government would have to pay for prescription drug patents. , 1997, Health economics.
[45] Henry G. Grabowski,et al. A New Look at the Returns and Risks to Pharmaceutical R&D , 1990 .
[46] V. Atella,et al. Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price. , 2000, Health policy.
[47] Michael J. Boskin,et al. Toward a More Accurate Measure of the Cost of Living , 1996 .
[48] R. Henderson,et al. Public-private interaction in pharmaceutical research. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[49] F. Lichtenberg. Do (more and better) drugs keep people out of hospitals? , 1996, The American economic review.
[50] Li-Wei Chao,et al. Does Regulation Drive Out Competition in Pharmaceutical Markets?* , 2000, The Journal of Law and Economics.
[51] P. Cavalié. Les références médicales opposables: quel impact sur la consommation de médicaments ? , 1998 .
[52] F. Tapon,et al. Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry. , 1985, Journal of health economics.
[53] F. Haaijer-Ruskamp,et al. Impact of feedback and peer review on prescribing. , 1995, Occasional paper.
[54] E. Berndt,et al. Treatment Price Indexes for Acute Phase Major Depression , 2001 .
[55] Michael R. Baye,et al. Demand systems and the true subindex of the cost of living for pharmaceuticals , 1997 .
[56] Z. Griliches,et al. Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs , 1996 .
[57] J. Hurley,et al. The Effects of Co-payments within Drug Reimbursement Programs , 1991 .
[58] Peter Temin,et al. Technology, Regulation, and Market Structure in the Modern Pharmaceutical Industry , 1979 .
[59] The Distribution and Pricing of Prescription Drugs , 1997 .
[60] F. Haaijer-Ruskamp,et al. Treatment of Uncomplicated Urinary Tract Infections: Exploring Differences in Adherence to Guidelines between Three European Countries , 2000, The Annals of pharmacotherapy.
[61] T. Abbott. Price regulation in the pharmaceutical industry: prescription or placebo? , 1995, Journal of health economics.
[62] A. Harris. Economic Appraisal in the Regulation of Pharmaceuticals in Australia: Its Rationale and Potential Impact , 1994 .
[63] G. Fattore,et al. The new pharmaceutical policy in Italy. , 1998, Health policy.
[64] P. Kanavos,et al. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. , 1997, Health policy.